Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Company Overview - Exelixis shares have decreased by approximately 7.2% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Exelixis have trended upward in the past month, with the consensus estimate shifting by 15.91% [2] VGM Scores - Exelixis has a strong Growth Score of A and a momentum score of A, with a value score of B, placing it in the top 40% for this investment strategy [3] - The aggregate VGM Score for Exelixis is A, indicating strong overall performance across multiple investment strategies [3] Outlook - The upward trend in estimates suggests a promising outlook for Exelixis, which holds a Zacks Rank 2 (Buy) [4] - An above-average return is expected from the stock in the upcoming months [4] Industry Performance - Exelixis is part of the Zacks Medical - Biomedical and Genetics industry, where Puma Biotech has gained 22.1% over the past month [5] - Puma Biotech reported revenues of $46 million for the last quarter, reflecting a year-over-year increase of 5% [5] - Puma Biotech's expected earnings for the current quarter are $0.11 per share, indicating a significant change of 320% from the previous year [6] - Puma Biotech also holds a Zacks Rank 2 (Buy) and has a VGM Score of A [6]